Grown Rogue International Inc. operates in the healthcare sector, focusing on the cultivation and sale of cannabis products in the U.S. The company shows strengths with a solid gross margin of 47.6% and a healthy current ratio of 2.59, indicating good liquidity. However, concerns arise from a negative net margin of -15.0% and a high debt-to-equity ratio of 1.79, suggesting potential financial strain. While the gross margin is strong, the overall financial health score of 52/100 reflects challenges in profitability and return metrics.
Loading financial metrics...
No significant red flags identified
This company appears financially healthy on available metrics
Exceptional revenue growth of 59.7% YoY demonstrates strong market demand and competitive positioning.
Operating cash flow of $4.7M exceeds net income by 2976%, indicating high-quality earnings with strong cash conversion.
Excellent liquidity with current ratio of 2.6x ensures operational stability.
Free cash flow increased 26.6% YoY, enhancing capital allocation optionality.
Strong free cash flow margin of 12.4% provides substantial resources for dividends, buybacks, or reinvestment.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Drug Manufacturers - Specialty & Generic companies of a similar size
Based on 2026-Q2 (June 30, 2026)